Met-G2 Tablet SR is a sustained-release oral antidiabetic medication combining Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and increases peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The sustained-release formulation ensures a gradual release of active ingredients, promoting better glycemic stability and reducing gastrointestinal side effects commonly associated with immediate-release metformin. Met-G2 Tablet SR is prescribed as an adjunct to diet and exercise when monotherapy is insufficient for achieving adequate glycemic control. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. Patient education on adherence, lifestyle modifications, and recognition of hypoglycemic symptoms is crucial for optimal therapeutic outcomes. Met-G2 Tablet SR should be used under medical supervision with periodic assessment of renal function and glycemic parameters.